Source: Annual Congress 2001 - Pulmonary hypertension: effect of iloprost
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. J. Roeleveld, A. Vonk Noordegraaf, J. T. Marcus, P. E. Postmus, A. Boonstra (Amsterdam, The Netherlands). Efficacy of epoprostenol treatment for pulmonary hypertension: hemodynamic and clinical improvement during the initial 8-month period. Eur Respir J 2001; 16: Suppl. 31, 2167

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of epoprostenol treatment in pulmonary hypertension: frequent follow-up by MRI combined with invasive measurements Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002 Long-term treatment with oral sildenafil in addition to chronic prostacyclin therapy improves pulmonary hemodynamics and six minute walking test in patients with pulmonary arterial hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 Effect of long-term oxygen therapy on exercise capacity and quality of life in exercise-desaturating patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomized-sham-controlled cross-over trial Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety. Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Efficacy of a 12 months oral sildenafil treatment in patients with severe pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 660s Year: 2006 Clinical and hemodynamic long term efficacy of sildenafil in primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005 Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-centre study Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Long-term benefits of pulmonary rehabilitation in COPD patients: 2 year follow-up Source: International Congress 2017 – Novel treatments for rehabilitation of patients with chronic respiratory diseases Year: 2017 Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001 Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013